Get started
Author

Raches Ella

ORCID: 0000-0002-4646-4471
Observed ORCID: 0000-0002-4646-4471
OpenAlex ID: A5025422454
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
2021 · Raches Ella, Krishna Mohan Vadrevu, et al. · The Lancet Infectious Diseases · 427
PDF
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
2021 · Raches Ella, Siddarth Reddy, et al. · The Lancet · 387
PDF
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
2021 · Raches Ella, Siddharth Reddy, et al. · The Lancet Infectious Diseases · 382
PDF
Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees
2021 · Pragya D Yadav, Gajanan N Sapkal, et al. · Clinical Infectious Diseases · 250
PDF
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2
2021 · Gajanan N Sapkal, Pragya D Yadav, et al. · Journal of Travel Medicine · 121
PDF
Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin
2021 · Pragya D Yadav, Gajanan N Sapkal, et al. · Journal of Travel Medicine · 109
PDF
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
2021 · Pragya D. Yadav, Raches Ella, et al. · Nature Communications · 106
PDF
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
2023 · Chandramani Singh, Savita Verma, et al. · npj Vaccines · 99
PDF
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
2021 · Brunda Ganneru, Harsh Jogdand, et al. · iScience · 94
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
2021 · Sreelekshmy Mohandas, Pragya D. Yadav, et al. · iScience · 71
Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum
2021 · Gajanan N. Sapkal, Pragya D. Yadav, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 55
PDF
Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine
2021 · Gajanan Sapkal, Pragya D Yadav, et al. · Journal of Travel Medicine · 44
PDF
Persisting antibody responses to Vi polysaccharide–tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination
2021 · Krishna Mohan Vadrevu, Dugyala Raju, et al. · Vaccine · 42
PDF
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
2022 · Raju Sunagar, Sai D. Prasad, et al. · Frontiers in Immunology · 40
PDF
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
2022 · Krishna Mohan Vadrevu, Brunda Ganneru, et al. · Scientific Reports · 40
PDF
Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
2021 · Pragya D. Yadav, Gajanan N. Sapkal, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 39
PDF
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
2022 · Krishna Mohan Vadrevu, Siddharth Reddy, et al. · The Lancet Infectious Diseases · 38
PDF
Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152
2020 · Brunda Ganneru, Harsh Jogdand, et al. · SSRN Electronic Journal · 30
Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine
2019 · Krishna Mohan Vadrevu, Venugopal Potula, et al. · The Journal of Infectious Diseases · 27
PDF
Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern
2022 · Gururaj Rao Deshpande, Pragya D Yadav, et al. · Journal of Travel Medicine · 24
A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India
2018 · Raches Ella, Radhika Bobba, et al. · Human Vaccines & Immunotherapeutics · 21
PDF
A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants
2019 · Raches Ella, Sudhir Babji, et al. · Vaccine · 19
PDF
A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial
2025 · Wilbur H. Chen, Robin S. Barnes, et al. · Nature Medicine · 14
PDF
Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
2021 · Gajanan Sapkal, Pragya D. Yadav, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 13
PDF
Immunogenicity and protective efficacy of BBV152: a whole virion inactivated SARS CoV-2 vaccine in the Syrian hamster model
2020 · Sreelekshmy Mohandas, Pragya D Yadav, et al. · 10
PDF
Works count: 34
Citation count: 2,531
H-index: 21
I10-index: 25
Year
Topic
Type